quinolonecarboxylic acid class of antibacterial agents and is currently undergoing clinical evaluation. We have developed efficient asymmetric syntheses of the enantiomers of this agent. The S-(+) enantiomer 1a is 1-2 log2 dilutions more active than the R-(-) enantiomer 1b against aerobic bacteria and 1-2 or more log2 dilutions more active against anaerobic bacteria in vitro. The enantiomer 1a shows
化合物1 [7-(
3-氨基吡咯烷-1-基)-1-(2,4-二
氟苯基)-1,4-二氢-6-
氟咯-4-羰基-
1,8-萘啶-3-羧酸盐酸]是
喹诺酮羧酸类抗菌剂的有效成员,目前正在临床评估中。我们已经开发了该试剂的对映异构体的有效不对称合成。在体外,S-(+)对映异构体1a的抗氧性比R-(-)对映异构体1b的活性高1-2个log2稀释,对厌氧菌具有1-2个或更多log2稀释。对映异构体1a在
铜绿假单胞菌小鼠保护模型中显示出比消旋体1更好的体内活性。再加上1a相对于消旋体材料的溶解度改善,从临床角度来看,这些特征可能具有实际意义。